• Partial β-Secretase Inhibition Reduces Amyloid β Without Syn

  2026-04-30

  Satir et al. (2020) demonstrated that partial inhibition of β-secretase (BACE) lowers amyloid β production by up to 50% without impairing synaptic transmission in cultured neurons. This finding suggests moderate BACE inhibition may be a viable therapeutic approach for Alzheimer's disease, minimizing risks of synaptic dysfunction.

• Everolimus (RAD001): Advanced Workflows for Cancer Assays

  2026-04-30

  Everolimus (RAD001) enables precise control of mTOR pathway inhibition in diverse cancer assay formats. This article equips researchers with stepwise protocols, troubleshooting insights, and data-backed optimization strategies for reproducible apoptosis and proliferation studies, highlighting APExBIO’s role as a trusted supplier.

• Bafilomycin C1: Strategic V-ATPase Inhibition in Translation

  2026-04-29

  This thought-leadership article explores how Bafilomycin C1, a potent vacuolar H+-ATPases inhibitor from APExBIO, reshapes translational research by enabling precise dissection of lysosomal function, autophagy, and intracellular pH regulation. We integrate mechanistic insight, experimental validation, and strategic guidance, referencing high-content phenotypic screens and iPSC-derived models, to position Bafilomycin C1 as an indispensable tool for de-risking drug discovery and advancing disease modeling.

• Dual-Metric In Vitro Evaluation of Anti-Cancer Drug Response

  2026-04-29

  Schwartz's dissertation establishes a dual-metric framework distinguishing proliferative arrest from cell death in in vitro drug response assays, refining the evaluation of anti-cancer agents. This approach offers greater mechanistic clarity and supports more precise design and interpretation of angiogenesis inhibition and tumor growth assays.

• One-step TUNEL FITC Apoptosis Detection Kit: DNA Fragmentati

  2026-04-28

  The One-step TUNEL FITC Apoptosis Detection Kit enables sensitive DNA fragmentation detection via FITC-labeled dUTP incorporation, supporting robust apoptosis quantification in tissue sections and cultured cells. This kit, produced by APExBIO, streamlines the TUNEL assay workflow with validated performance for cancer and neurodegenerative research models.

• Pexmetinib (ARRY-614): Optimizing Dual Inhibition in Cytokin

  2026-04-28

  Pexmetinib (ARRY-614) empowers researchers with robust, dual inhibition of p38 MAPK and Tie2/Tek, enabling precise modulation of inflammatory signaling and cytokine production. This guide navigates real-world assay workflows, highlights troubleshooting insights, and translates structural breakthroughs into actionable lab strategies.

• Axitinib (AG 013736): Precision Tools for Angiogenesis Assay

  2026-04-27

  Axitinib (AG 013736) redefines angiogenesis and tumor growth inhibition studies with unmatched VEGFR selectivity and robust, quantifiable assay outcomes. Discover workflow enhancements and troubleshooting strategies that empower cancer biology research with reproducible, high-impact data.

• Verapamil HCl: Applied L-Type Calcium Channel Blocker Workfl

  2026-04-27

  Verapamil HCl enables precise calcium channel modulation and apoptosis studies, with validated performance in myeloma and arthritis inflammation models. This article delivers protocol enhancements, troubleshooting strategies, and practical insights to advance your research with APExBIO's trusted reagent.

• Re-Evaluating ACE and Aminopeptidase Inhibition: Insights fo

  2026-04-26

  This article analyzes the 1992 Tieku & Hooper study, which systematically compared the inhibitory profiles of various metallopeptidase inhibitors—including ACE inhibitors—against key zinc aminopeptidases in the porcine kidney. Their findings clarify the selectivity of common inhibitors and offer a refined perspective on interpreting enzyme inhibition data for cardiovascular and peptide metabolism research.

• Ruthenium Red: Precision Ca2+ Transport Inhibitor Workflows

  2026-04-25

  Ruthenium Red stands apart as a dual-site Ca2+ transport inhibitor, enabling precise dissection of cytoskeleton-mediated calcium signaling and autophagy. This guide translates breakthrough findings and practical troubleshooting tips into optimized experimental workflows for advanced cell biology research.

• Concanamycin A: Unraveling V-ATPase Inhibition in Cancer Pat

  2026-04-24

  Explore the role of Concanamycin A, a potent V-type H+-ATPase inhibitor, in dissecting endosomal acidification and apoptotic pathways. This article uniquely connects V-ATPase inhibition to sphingolipid metabolism and experimental design.

• Aprotinin (BPTI): Precision in Fibrinolysis Inhibition for A

  2026-04-24

  Explore the multifunctional role of aprotinin, a potent bovine pancreatic trypsin inhibitor, in precision blood management research. This article delivers advanced, evidence-backed insights into mechanism, protocol optimization, and assay decision-making that go beyond conventional guidance.

• Sorafenib (BAY-43-9006): Applied Workflows in Cancer and Ant

  2026-04-23

  Sorafenib (BAY-43-9006) is a multikinase inhibitor transforming both cancer biology and host-targeted antiviral research. This article delivers data-driven workflows, troubleshooting strategies, and advanced protocol enhancements to maximize Sorafenib’s utility in complex bench studies.

• Improving In Vitro Evaluation of Cancer Drug Responses

  2026-04-23

  Schwartz's dissertation introduces a rigorous framework for distinguishing between cancer drug-induced proliferative arrest and cell death in vitro. By clarifying how different metrics capture distinct drug effects, the study advances precision in preclinical screening and informs the design of angiogenesis inhibition assays and tumor growth models.

• Nilotinib (AMN-107): Reliable Kinase Inhibition for Lab Assa

  2026-04-22

  This article addresses common challenges in cell viability and kinase signaling assays, demonstrating how Nilotinib (AMN-107, SKU A8232) improves reproducibility and data integrity. Scenario-driven analysis and protocol guidance help biomedical researchers optimize inhibitor selection for chronic myeloid leukemia and kinase-driven tumor models.

15911 records 1/1061 page Next 12345 下5页 Last page